Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 9, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma
It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research conducted at Queen Mary University of London, up to 64% of antiobiotics made and sold in India are unapproved.
Elsewhere, the M&A engine keeps chugging as Allergan snapped up Elastagen and its skincare molecule for $95 million. But the most popular news this week was the blow dealt to Novartis as it learned its generic version to GSK’s Advair will be delayed to market.
Also, be sure not miss our special feature on AI and how it is poised to revolutionise pharma and life sciences, featuring comment from GSK and Exscientia on their AI drug development partnership.
Top Ten most popular articles on Pharmafile.com this week!
10. Allergan’s Avycaz becomes first FDA-approved gram-negative antibiotic in over 15 years
The FDA has awarded approval to Allergan’s fixed-dose combination antibacterial Avycaaz for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adult patients.
9. Faslodex rejected by NICE for NHS breast cancer use
Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it has decided to reject AstraZeneca’s Faslodex (fulvestrant) on the basis that it cannot reconcile its cost-effectiveness for use on the NHS.
8. Theravance seals potential $1bn deal with J&J
Johnson & Johnson is the latest to join the burgeoning field of JAK inhibitor developers, with a prospective $1 billion deal with Theravance Biopharma.
7. 64% of FDC antibiotics in India are unapproved, report reveals
The majority of fixed dose combination (FDC) antibiotics that are made and sold in India are still unapproved, a study by researchers at Queen Mary University of London and Newcastle University has revealed.
6. Rapidly-growing Nektar Therapeutics reportedly considering sale of its business
The next major sale in the industry could be for Nektar Therapeutics, who is reported by Bloomberg to be looking into the sale of its business.
5. Two former Greek PMs implicated in Novartis bribery case
An ongoing investigated case into Novartis sales practices in Greece has so far implicated 10 current and former politicians, regarding alleged incidences of bribery between 2006 and 2015.
4. The future is now: The transformative power of AI
With the technologies reaching exciting levels of maturity and adoption, Matt Fellows investigates how AI and machine learning can be transformative for some of pharma’s age-old problems.
3. Array’s melanoma therapy blasts Roche’s out of water
Array Biopharma has seemingly bounced back from an aborted application to the FDA by switching its focus to the treatment of BRAF-mutant melanoma, where binimetinib combined with encorafenib resulted in an improvement to median overall survival by 33.6 months.
2. Allergan bolsters skincare portfolio with Elastagen acquisition for $95 million
Pharma’s M&A train keeps on going as news breaks that Allergan has picked up University of Sydney spin-off Elastagen for $95 million.
1. Novartis tastes own medicine, Advair generic delayed
Novartis has been hit by the news that its generic version to GSK’s Advair has been rejected by the FDA, scuppering its plans for a launch this year.
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
